Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

This study has been completed.
Information provided by (Responsible Party):
Mochida Pharmaceutical Company, Ltd. Identifier:
First received: June 29, 2010
Last updated: January 8, 2014
Last verified: October 2013

This is a controlled study to determine the effectiveness and safety of ethyl icosapentate (EPA-E) in the treatment of adult patients with non-alcoholic steatohepatitis (NASH).

Condition Intervention Phase
Drug: Placebo
Drug: EPA-E
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH

Resource links provided by NLM:

Further study details as provided by Mochida Pharmaceutical Company, Ltd.:

Primary Outcome Measures:
  • Histological response defined by change from baseline in standardized scoring of liver biopsies [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Alanine transaminase (ALT) levels [ Time Frame: 3 months and 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall histological score [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Individual histological feature scores [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 243
Study Start Date: June 2010
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Placebo capsule three times a day (TID) for 365 days
Experimental: EPA-E 1800 mg/day Drug: EPA-E
600 mg capsule TID for 365 days
Experimental: EPA-E 2700 mg/day Drug: EPA-E
900 mg capsule TID for 365 days

Detailed Description:

This is a phase II, double-blinded, placebo-controlled study to investigate the safety, efficacy, and pharmacokinetic profile of two doses of EPA-E in adult subjects with NASH. Subjects are required to have a liver biopsy with proven NASH in the 6 month period prior to screening. Up to 70 subjects will be enrolled into each treatment arm in a 1:1:1 ratio, for a total of 210 subjects. Subjects will be stratified at randomization by presence or absence of diabetes. Duration of treatment is 12 months.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of definite NASH
  • Patients with diabetes taking stable doses of anti-diabetic agents are eligible
  • No significant concomitant medical illness

Exclusion Criteria:

  • Diagnosis of cirrhosis.
  • Serum ALT > 300 U/L
  • Use of drugs associated with steatohepatitis
  • Use of the following anit-NASH agents:

    1. Vitamin E > 60 IU per day
    2. Omega-3-acid ethyl esters or omega-3-polyunsaturated fatty acid (PUFA)-containing supplements > 200 mg per day
    3. Thiazolidinediones (e.g. pioglitazone)
  • Use of non-stable doses of the following anti-NASH agents: HMGCoA reductase inhibitors (statins), fibrates, probucol, ezetimibe, ursodiol (UDCA), taurine, betaine, N-acetylcysteine, s-adenosylmethionine (SAM-E), milk thistle, anti-TNF therapies, or probiotics.
  • Other liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01154985

  Show 34 Study Locations
Sponsors and Collaborators
Mochida Pharmaceutical Company, Ltd.
  More Information

No publications provided by Mochida Pharmaceutical Company, Ltd.

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Mochida Pharmaceutical Company, Ltd. Identifier: NCT01154985     History of Changes
Other Study ID Numbers: MCH-02-001
Study First Received: June 29, 2010
Last Updated: January 8, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Mochida Pharmaceutical Company, Ltd.:
omega-3 fatty acids
alanine transaminase
ethyl icosapentate
Non Alcoholic steatohepatitis
Non Alcoholic fatty liver disease
fatty acids

Additional relevant MeSH terms:
Fatty Liver
Digestive System Diseases
Liver Diseases
Eicosapentaenoic acid ethyl ester
Hematologic Agents
Pharmacologic Actions
Platelet Aggregation Inhibitors
Therapeutic Uses processed this record on October 22, 2014